Astellas sales and marketing update

Astellas launched Xtandi enzalutamide in Japan to treat castration-resistant prostate cancer (CRPC). Japan's National Health Insurance (NHI) price for the drug is ¥3,138.80 ($30.76) for a 40 mg capsule. The recommended dose is 160 mg once daily. The oral androgen receptor antagonist is already approved in more than 35 countries, including the U.S. and EU, for CRPC patients previously treated with docetaxel. ...